MedKoo Cat#: 414057 | Name: Tazemetostat HBr
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tazemetostat (EPZ-6438, E7438) is a potent, selective, and orally bioavailable small-molecule inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase involved in epigenetic gene silencing. It inhibits both wild-type and mutant EZH2 (e.g., Y641 and A677 mutations) with nanomolar potency—IC₅₀ values of 2.5 nM (Y641N), 11 nM (Y641F), and 4.7 nM (wild-type EZH2) in biochemical assays. In cellular models, Tazemetostat leads to a reduction in trimethylation of histone H3 at lysine 27 (H3K27me3) and induces antiproliferative effects in EZH2-mutant diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma cells. In xenograft models, oral administration of Tazemetostat significantly reduces tumor growth with favorable pharmacokinetic properties and minimal toxicity. These properties support its clinical development, and it is currently FDA-approved for certain relapsed/refractory follicular lymphomas and epithelioid sarcomas.

Chemical Structure

Tazemetostat HBr
Tazemetostat HBr
CAS#1467052-75-0 (HBr)

Theoretical Analysis

MedKoo Cat#: 414057

Name: Tazemetostat HBr

CAS#: 1467052-75-0 (HBr)

Chemical Formula: C34H45BrN4O4

Exact Mass: 0.0000

Molecular Weight: 653.66

Elemental Analysis: C, 62.47; H, 6.94; Br, 12.22; N, 8.57; O, 9.79

Price and Availability

Size Price Availability Quantity
100mg USD 450.00 2 Weeks
250mg USD 850.00 2 Weeks
500mg USD 1,250.00 2 Weeks
1g USD 2,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Tazemetostat HBr; Tazemetostat hydrobromide; EPZ 6438; EPZ-6438; EPZ6438; E7438; E7438; E7438;
IUPAC/Chemical Name
(1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1)
InChi Key
UQRICAQPWZSJNF-UHFFFAOYSA-N
InChi Code
InChI=1S/C34H44N4O4.BrH/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40;/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40);1H
SMILES Code
O=C(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(N(CC)C4CCOCC4)=C1C)NCC5=C(C)C=C(C)NC5=O.[H]Br
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 653.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang J, Yang M, Liu Q, Xue X, Tian S, Hu X, Li M, Li J, Chai Q, Liu F, You X, Zhang Y. Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies. Bioorg Chem. 2024 Dec;153:107964. doi: 10.1016/j.bioorg.2024.107964. Epub 2024 Nov 19. PMID: 39571304. 2: Lee J, You C, Kwon G, Noh J, Lee K, Kim K, Kang K, Kang K. Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma. Cell Death Dis. 2024 Nov 8;15(11):801. doi: 10.1038/s41419-024-07198-0. PMID: 39516467; PMCID: PMC11549485. 3: Geethadevi A, Raabe EH. Approaches for prevention of tumors in patients with rhabdoid tumor predisposition syndrome. Neurooncol Adv. 2024 Sep 12;6(1):vdae158. doi: 10.1093/noajnl/vdae158. PMID: 39434925; PMCID: PMC11491493. 4: Gold S, Shilatifard A. Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges. J Clin Invest. 2024 Oct 15;134(20):e183391. doi: 10.1172/JCI183391. PMID: 39403928; PMCID: PMC11473148. 5: Kikuchi S, Nabe Y, Horaguchi R, Minemura T, Murakami J, Noguchi A, Takagi K, Kamihara Y, Wada A, Fujihira T, Sato T. Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase. Int Cancer Conf J. 2024 Aug 21;13(4):488-492. doi: 10.1007/s13691-024-00716-z. PMID: 39398919; PMCID: PMC11465062. 6: Jiang W, Liu L, Wang M, Li X, Zhou T, Hou X, Qiao L, Chen C, Zuo D, Liu J, Ren L. KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability. Cell Mol Life Sci. 2024 Oct 5;81(1):417. doi: 10.1007/s00018-024-05442-6. PMID: 39367978; PMCID: PMC11455850. 7: Hou Y, Zak J, Shi Y, Pratumchai I, Dinner B, Wang W, Qin K, Weber EW, Teijaro JR, Wu P. Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T-cell stemness and improves adoptive T-cell therapy. Cancer Immunol Res. 2024 Oct 4. doi: 10.1158/2326-6066.CIR-24-0089. Epub ahead of print. PMID: 39365901. 8: Maruyama D. [Current standard treatments and future outlook for follicular lymphoma]. Rinsho Ketsueki. 2024;65(9):1004-1011. Japanese. doi: 10.11406/rinketsu.65.1004. PMID: 39358254. 9: Fu M, Wang Y, Ge M, Hu C, Xiao Y, Ma Y, Gou S. Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway. Bioorg Med Chem Lett. 2024 Nov 15;113:129968. doi: 10.1016/j.bmcl.2024.129968. Epub 2024 Sep 16. PMID: 39293534. 10: Schiano C, Trama U, Coscioni E, Infante T, Coppola A, de Nigris F, Napoli C. Epitranscriptome: A Novel Regulatory Layer during Atherosclerosis Progression. Curr Med Chem. 2024 Aug 30. doi: 10.2174/0109298673322775240822051304. Epub ahead of print. PMID: 39219432. 11: Kumar EA, Korfi K, Bewicke-Copley F, Close K, Heward J, Witzig T, Leukam M, Ansell S, Scott J, Clear A, Efeyan A, Green M, Siebert R, Peck B, Calaminici M, Wang J, Smith S, Novak A, Fitzgibbon J, Okosun J. CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma. Br J Haematol. 2024 Nov;205(5):1804-1809. doi: 10.1111/bjh.19671. Epub 2024 Aug 26. PMID: 39188028. 12: Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S. Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. Int J Hematol. 2024 Nov;120(5):621-630. doi: 10.1007/s12185-024-03834-9. Epub 2024 Aug 23. PMID: 39179948; PMCID: PMC11513718. 13: Hsu C, Konner JA, Gounder MM. Epigenetic Therapy in a Rare Ovarian Cancer - A Double-Edged Sword. N Engl J Med. 2024 Aug 22;391(8):770-772. doi: 10.1056/NEJMc2407971. PMID: 39167815. 14: Taheri N, Choi EL, Nguyen VTT, Zhang Y, Huynh NM, Kellogg TA, van Wijnen AJ, Ordog T, Hayashi Y. Inhibition of EZH2 Reduces Aging-Related Decline in Interstitial Cells of Cajal of the Mouse Stomach. Cell Mol Gastroenterol Hepatol. 2024;18(4):101376. doi: 10.1016/j.jcmgh.2024.101376. Epub 2024 Jul 3. PMID: 38969206; PMCID: PMC11359770. 15: Fu F, Zhang Y, Shen H. [Advances in Targeted Therapy for Malignant Pleural Mesothelioma]. Zhongguo Fei Ai Za Zhi. 2024 May 20;27(5):391-398. Chinese. doi: 10.3779/j.issn.1009-3419.2024.102.18. PMID: 38880927; PMCID: PMC11183316. 16: Rajput N, Jadav T, Sengupta P. Identification and characterization of the rat in-vivo and in-vitro metabolites of tazemetostat using LC-QTOF-MS. Food Chem Toxicol. 2024 Aug;190:114785. doi: 10.1016/j.fct.2024.114785. Epub 2024 Jun 6. PMID: 38849047. 17: Buteyn NJ, Burke CG, Sartori VJ, Deering-Gardner E, DeBruine ZJ, Kamarudin D, Chandler DP, Monovich AC, Perez MW, Yi JS, Ries RE, Alonzo TA, Ryan RJ, Meshinchi S, Triche TJ Jr. EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion. bioRxiv [Preprint]. 2024 Jun 25:2024.05.14.594150. doi: 10.1101/2024.05.14.594150. PMID: 38798454; PMCID: PMC11118270. 18: O'Donnell E, Muñoz M, Davis R, Randall RL, Tepper C, Carr-Ascher J. Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic Target. bioRxiv [Preprint]. 2024 May 14:2024.05.14.594060. doi: 10.1101/2024.05.14.594060. PMID: 38798385; PMCID: PMC11118861. 19: Orleni M, Parise RA, Holleran JL, Amengual JE, Feng Y, Synold T, Beumer JH. Quantitation of tazemetostat in human plasma using liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2024 Jul;38(7):e5903. doi: 10.1002/bmc.5903. Epub 2024 May 23. PMID: 38783541. 20: Kazansky Y, Mueller HS, Cameron D, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Mundi PS, Kuwahara Y, Somwar R, Qu R, Califano A, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas. bioRxiv [Preprint]. 2024 May 6:2024.05.03.592420. doi: 10.1101/2024.05.03.592420. PMID: 38766189; PMCID: PMC11100591.